Literature DB >> 23719685

Does high-dose radiotherapy benefit palliative lung cancer patients?: An intradepartmental comparison of two dose regimens.

C Schröder1, M Ivo, A Buchali.   

Abstract

BACKGROUND AND
PURPOSE: The present analysis compares two palliative treatment concepts for lung cancer in terms of overall survival. PATIENTS AND METHODS: Survival data from 207 patients were used in a retrospective analysis. All patients received palliative treatment comprising either 25 Gy applied in 5 fractions or 50 Gy in 20 fractions. A subgroup analysis was performed to compare patients with a good-fair vs. poor overall condition.
RESULTS: Median survival times were 21 weeks (range 6-26 weeks) for patients treated with 25 Gy in 5 fractions and 23 weeks (range 14.5-31.5 weeks) for patients treated with 50 Gy in 20 fractions (95 % confidence interval, CI; p = 0.334). For patients with a good-fair overall condition, median survival times were 30 weeks (21.8-39.2 weeks) for 25 Gy in 5 fractions and 28 weeks (14.2-41.8 weeks) for 50 Gy in 20 fractions (CI 95 %, p = 0.694). In patients with a poor overall condition, these values were 18 weeks (14.5-21.5 weeks) and 21 weeks (13.0-29.0 weeks), respectively (CI 95 %, p = 0.248).
CONCLUSION: The palliative treatment concept of 25 Gy applied in 5 fractions is sufficient for radiation of lung cancer, given that there was no obvious survival improvement in patients treated with the higher total dose regimen.

Entities:  

Mesh:

Year:  2013        PMID: 23719685     DOI: 10.1007/s00066-013-0360-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  24 in total

Review 1.  Palliative thoracic radiotherapy for lung cancer: a systematic review.

Authors:  Alysa Fairchild; Kristin Harris; Elizabeth Barnes; Rebecca Wong; Stephen Lutz; Andrea Bezjak; Patrick Cheung; Edward Chow
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

2.  Palliative radiotherapy for lung cancer: two versus five fractions.

Authors:  G J Rees; C E Devrell; V L Barley; H F Newman
Journal:  Clin Oncol (R Coll Radiol)       Date:  1997       Impact factor: 4.126

3.  Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial.

Authors:  J R Simpson; M E Francis; R Perez-Tamayo; R D Marks; D V Rao
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-04       Impact factor: 7.038

4.  Palliative radiation for stage 3 non-small cell lung cancer--a prospective study of two moderately high dose regimens.

Authors:  R P Abratt; L J Shepherd; D G Salton
Journal:  Lung Cancer       Date:  1995-10       Impact factor: 5.705

5.  Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).

Authors:  Andrea Bezjak; Peter Dixon; Michael Brundage; Dong Tu; Michael J Palmer; Paul Blood; Clive Grafton; Catherine Lochrin; Carson Leong; Liam Mulroy; Colum Smith; James Wright; Joseph L Pater
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

6.  A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study.

Authors:  U Nestle; C Nieder; K Walter; U Abel; D Ukena; G W Sybrecht; K Schnabel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

Review 7.  Palliative percutaneous radiotherapy in non-small-cell lung cancer.

Authors:  Wilfried Budach; Claus Belka
Journal:  Lung Cancer       Date:  2004-08       Impact factor: 5.705

Review 8.  Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer.

Authors:  Chaundré K Cross; Stuart Berman; Lori Buswell; Bruce Johnson; Elizabeth H Baldini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

9.  Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.

Authors:  Stein Sundstrøm; Roy Bremnes; Ulf Aasebø; Steinar Aamdal; Reidulv Hatlevoll; Paal Brunsvig; Dag Clement Johannessen; Olbjørn Klepp; Peter M Fayers; Stein Kaasa
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

10.  Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline.

Authors:  George Rodrigues; Gregory M M Videtic; Ranjan Sur; Andrea Bezjak; Jeffrey Bradley; Carol A Hahn; Corey Langer; Keith L Miller; Benjamin J Moeller; Kenneth Rosenzweig; Benjamin Movsas
Journal:  Pract Radiat Oncol       Date:  2011-04-08
View more
  6 in total

1.  Impact of comorbidity on survival after palliative radiotherapy.

Authors:  Carsten Nieder; Kirsten Engljähringer; Kent Angelo
Journal:  Strahlenther Onkol       Date:  2014-07-15       Impact factor: 3.621

2.  Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer.

Authors:  B van Oorschot; B Assenbrunner; M Schuler; G Beckmann; M Flentje
Journal:  Strahlenther Onkol       Date:  2014-01-12       Impact factor: 3.621

3.  How Should Palliative Thoracic Radiotherapy Be Fractionated for Octogenarians with Lung Cancer?

Authors:  Carsten Nieder; Rosalba Yobuta; Bård Mannsåker; Astrid Dalhaug
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

4.  Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while?

Authors:  Malene Støchkel Frank; Dorte Schou Nørøxe; Lotte Nygård; Gitte Fredberg Persson
Journal:  BMC Palliat Care       Date:  2018-01-05       Impact factor: 3.234

5.  Palliative Thoracic Radiotherapy for Lung Cancer: What Is the Impact of Total Radiation Dose on Survival?

Authors:  Carsten Nieder; Terje Tollali; Rosalba Yobuta; Anne Reigstad; Liv Randi Flatoy; Adam Pawinski
Journal:  J Clin Med Res       Date:  2017-04-26

6.  Nontargeted Effect after Radiotherapy in a Patient with Non-Small Cell Lung Cancer and Bullous Pemphigoid.

Authors:  Carsten Nieder; Khalid Al-Shibli; Terje Tollåli
Journal:  Case Rep Oncol Med       Date:  2015-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.